Product image of Nakom Mite (Carbidopa, Levodopa) supplied by GNH India

Nakom Mite

Active Ingredient:
Carbidopa, Levodopa
Origin:
EU

Nakom Mite (Carbidopa, Levodopa)

Carbidopa/Levodopa, the active ingredient in Nakom Mite, is an Antiparkinson agent presented as an oral tablet for oral use. It treats Parkinson's disease and related Parkinsonian syndromes by restoring dopamine activity in the central nervous system.

GNH India supplies Nakom Mite as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Lek Pharmaceuticals D.D. Ljubljana

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Carbidopa/Levodopa is used in the management of movement disorders within the Parkinsonian disease spectrum.

  • Parkinson's disease: improves motor symptoms such as bradykinesia, rigidity and tremor.
  • Parkinsonian syndrome: alleviates similar motor deficits caused by secondary Parkinsonism.
  • Levodopa‑responsive Parkinsonism: provides symptomatic relief when dopamine deficiency is the primary driver.

How It Works

  • Levodopa crosses the blood‑brain barrier and is decarboxylated to dopamine, replenishing central dopaminergic tone. Carbidopa inhibits peripheral aromatic L‑amino acid decarboxylase, preventing premature conversion of levodopa outside the brain, thereby increasing central availability and reducing peripheral side effects.

Side Effects

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

  • Nausea: gastrointestinal upset occurring early in treatment.
  • Orthostatic hypotension: dizziness upon standing due to vasodilation.
  • Insomnia: difficulty initiating or maintaining sleep.
  • Headache: mild to moderate cranial discomfort.
  • Dyskinesia: involuntary movements, especially at higher doses.

Serious or Rare Side Effects

  • Hallucinations: visual or auditory disturbances requiring medical review.
  • Severe hypotension: marked blood pressure drop leading to syncope.
  • Neuroleptic malignant syndrome: rare but life‑threatening reaction.
  • Severe depression or suicidal ideation: mood changes needing urgent attention.
  • Cardiac arrhythmias: irregular heart rhythms in susceptible individuals.

Precautions & Warnings

Before initiating therapy, clinicians should consider several safety measures.

  • Monitor blood pressure: watch for orthostatic changes, especially in the elderly.
  • Assess for dyskinesia: adjust dose if involuntary movements emerge.
  • Avoid abrupt discontinuation: taper gradually to prevent withdrawal.
  • Use caution in cardiac disease: patients with arrhythmias may need closer observation.
  • Contraindicated in narrow‑angle glaucoma: may exacerbate intra‑ocular pressure.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Avoid Interactions

Carbidopa/Levodopa can interact with several medication classes, altering efficacy or safety.

Major Interactions (Avoid)

  • Non‑selective MAO inhibitors: risk of hypertensive crisis.
  • Antipsychotics (dopamine antagonists): may diminish therapeutic effect.
  • Alpha‑blockers: can potentiate orthostatic hypotension.

Moderate Interactions (Monitor Closely)

  • SSRIs and SNRIs: may increase risk of serotonin syndrome.
  • Iron or calcium supplements: reduce levodopa absorption; separate dosing by at least 2 hours.
  • High‑protein meals: compete for transport across the blood‑brain barrier, potentially lowering efficacy.

Frequently Asked Questions

Nakom Mite contains the combination of carbidopa and levodopa and is prescribed to manage the motor symptoms of Parkinson's disease and other Parkinsonian syndromes. It helps improve movement, reduce rigidity, and control tremor in patients with dopamine deficiency.

Levodopa is a precursor that crosses the blood‑brain barrier and is converted into dopamine, restoring deficient neurotransmission. Carbidopa inhibits the peripheral enzyme aromatic L‑amino acid decarboxylase, preventing premature conversion of levodopa outside the brain, which increases central availability and reduces peripheral side effects.

The dosage of Nakom Mite is individualized. A qualified prescriber determines the appropriate strength and dosing schedule based on the patient’s clinical condition, response, and tolerability. Patients should follow the prescribing information provided by their healthcare professional.

Safety data for carbidopa/levodopa in pregnancy and lactation are limited. The product is classified as pregnancy category unknown, and it should only be used if the potential benefit justifies any potential risk to the fetus. Breastfeeding mothers should consult their physician before use.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nakom Mite combines carbidopa with levodopa, offering a balanced approach that maximizes central dopamine production while limiting peripheral side effects. Compared with dopamine agonists, it provides more robust symptom control but may have a higher risk of motor complications such as dyskinesia. Choice of therapy depends on disease stage and individual patient factors.

Nakom Mite should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Nakom Mite is taken orally, usually with a small amount of food to reduce gastrointestinal upset. Tablets should be swallowed whole with water and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious risks include the development of dyskinesias, hallucinations, severe orthostatic hypotension, neuroleptic malignant syndrome, and rare cardiac arrhythmias. Patients should be monitored regularly, and any new or worsening symptoms should be reported to a clinician promptly.

Nakom Mite is contraindicated in patients with narrow‑angle glaucoma, known hypersensitivity to carbidopa or levodopa, and those taking non‑selective MAO inhibitors. Caution is advised for individuals with significant cardiovascular disease, severe hepatic impairment, or a history of psychotic disorders.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Carbidopa, Levodopa

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT